Full Press Release Details
SAN RAFAEL, Calif. , Nov. 6, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will host an R&D Day at 8:00am ET on Thursday, November 14, 2019 . BioMarin management and external experts will provide an update to the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare diseases.
BioMarin R&D Day 2019 Agenda
Welcome and Opening Remarks
Vosoritide for Achondroplasia and Other Indications
R&D Pipeline Deep Dive including PKU Gene Therapy Program Update
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Closing Statements
Live Audio Webcast Interested parties may access a live audio webcast that will include audio and slides of the presentations here . A replay of the event will be archived on the Events and Presentations page under the Investors/Media section of the Company's website for at least two weeks following the event.
For those who choose not to listen to the event via webcast, dial-in information for the audio portion of the webcast can be accessed using:
USA : (913) 227-1201 USA / Canada (toll free): (866) 705-2554 Conference ID: 6342187
About BioMarin BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com . Information on BioMarin's website is not incorporated by reference into this press release.
| Contacts: | |
| Investors | Media |
| Traci McCarty | Debra Charlesworth |
| BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
| (415) 455-7558 | (415) 455-7451 |
SOURCE BioMarin Pharmaceutical Inc.